Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection

Antivir Ther. 2024 Feb;29(1):13596535221097495. doi: 10.1177/13596535221097495.

Abstract

We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

Keywords: allogeneic stem cell transplant recipient; bamlanivimab; immune escape; mutation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Antibodies, Neutralizing
  • COVID-19* / diagnosis
  • Cross Infection* / drug therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Mutation
  • SARS-CoV-2
  • Stem Cell Transplantation

Substances

  • bamlanivimab
  • Antibodies, Neutralizing
  • Antibodies, Monoclonal, Humanized